We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: MLD384/13/2007 12:11:54 PM
   of 255
ARDM.OB : Michael Shulman, ChangeWave Biotech promo

Michael Shulman, ChangeWave Biotech Investor wrote in the promo:
..."I want you to look ahead to all the new opportunities we can share together. In fact, I've just created a new Video Alert on another little biotech that could double in a flash, on the way to another 5-bagger. It's yours FREE to watch by clicking here now:

Some of the written material on the webpage with the video:

..."The next stock to double in a flash -- Guaranteed? Of course not – this is what I call a “bleeding edge” biotech…a company – like Dendreon when I first recommended it – that still has challenges ahead of it. Yet, interestingly, this company is also a fairly mature company in many ways – and that takes a lot of the risk out of your investment now. Especially at today’s price. Every share you buy today costs about a buck-and-a-half. So you get a lot of leverage for just a small investment now. My target? $6.50 a share – a very nice move from here. When I say the company is fairly mature, here’s what I mean: They’ve raised a lot of cash through the years. And their science and technology is great. That’s the good news. The bad news is old news. Management fumbled the ball for years. And frankly, Wall Street lost patience, especially as the company recapitalized – as they actually eliminated many of their old problems in the process. Recently, the stock is acting better, so you want to establish your position now. While I consider this company a mid-to long-term hold – playing out over the next couple years – this stock has the potential, like Dendreon, to suddenly jump out fast. If that happens, our long-term investment will become a trade instead, as we double, or triple, our money virtually overnight."...


NOTE: I do not subscribe to Michael Schulman's ChangeWave BioTech newsletter, but I think ARDM.OB was the unnamed stock he discussed in the promo video. I do not know what the recommendations say ( ie buy, sell, hold, or short ... or at what share price, etc. ), but here are the titles of some of his recent BioTech alerts, etc.

04/12/2007 Catching Up With Spectrum and Nektar Biotech
04/05/2007 Speculation versus Investing Biotech
04/04/2007 New Buy Recommendation: Aradigm (ARDM) Biotech

ARDM had increased price and volume around April 4 - April 13

Stock quotes for ARDM.OB, NKTR, SPPI



Insiders: SEC Form 4

01/25/07 is the Date of Event Requiring Statement of Tang's Initial Statement of Beneficial Ownership of Securities Form 3
Tang Capital Partners, LP. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP. filed


...products are being developed for the treatment of a variety of diseases such as diabetes, cystic fibrosis, inhalation anthrax and pulmonary arterial hypertension. The company is also investigating the use of its technologies for other important therapeutic applications....
Aradigm : Novo Nordisk
...Aradigm is partnered with Novo Nordisk as well as several other biotechnology and pharmaceutical companies in the delivery of compounds via the AERx technology....
...contract manufacturing agreement with Novo Nordisk Delivery Technologies, Aradigm has access to manufacturing capacities that include over 200,000 square feet dedicated to commercial scale production and houses equipment such as the AERx Strip line (left). This single facility, when complete, will have the capacity to manufacture up to 750 million dosage forms a year....
Mgmt, directors, advisors:


Financials: loss for the year ended December 31, 2006 was $13.0 million, or $0.89 per share, compared with a net loss of $29.2 million, or $2.01 per share, for the same period in 2005. The year-over-year reduction in net loss was driven primarily by the recognition of an $8 million gain on sale of royalty interest and a $12 million gain on sale of patents, both transactions with Novo Nordisk, a related party....
Dr. Igor Gonda, Aradigm's President and CEO:
..."Our cash burn for the fourth quarter, and as we move into 2007, was below $2 million per month. With the proceeds of our recent public offering, we are in a strong financial position to support our new strategic initiatives aimed at becoming a specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists."...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext